|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Measurement of soilthermal properties by spherical probe 显示文摘 | Milun S Kilic T Bego O | 2005 | IEEETransactions on Instrumentation and Measurement2005，54，3： | 1 |
| 2 | Risk Factors for Preeclampsia:Results from a Cohort of Over 5000 Pregnancies in Spain显示文摘Objective:To determine the incidence of preeclampsia(PE)and preterm PE in Spain and to identify the risk factors for developing the disease.Methods:This is a multicenter prospective cohort study performed at six maternity units across Spain.Women with singleton pregnancies attending their first-trimester routine visit at the hospital were offered participation.Maternal and pregnancy characteristics,including mean arterial pressure,as well as ultrasound findings were recorded.Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for subsequent development of PE.Results:A total of 5868 pregnancies were recruited for this study,including 174(3.0%)cases of PE,47(0.8%)cases of preterm PE and 127(2.2%)cases of term PE.Median maternal age was 33.9 years(interquartile range:30.1 to 36.9)and median gestational age at the routine visit was 12.7 weeks(interquartile range:12.3 to 13.0).However,293(5.0%)of the women were on aspirin treatment during pregnancy,likely reducing the true incidence of the disease.As expected,increasing body mass index(P<0.001),uterine artery pulsatility index(P=0.011)and mean arterial pressure(P<0.001),assisted conception(P=0.013),previous personal(P<0.001)or family history of PE(P=0.024)and chronic hypertension(P=0.001)were identified as independent risk factors for developing subsequent PE during pregnancy.Screening for PE by maternal factors alone leads to a detection rate of 36.8%(64/174)at 10.0%(587/5868)screen positive rate.Conclusion:In Spain,3.0%of singleton pregnancies are complicated by PE and 0.8%require delivery before term due to its severity.Screening of PE by risk factors alone is only able to detect about 40%of total PE at 10%screen-positive rate. | Diana Cuenca Valeria Rolle Katy de Paco Matallana Nuria Valiño Rocio Revello Begoña Adiego Manel Mendoza Belen Santacruz Maria del Mar Gil | 2021 | Maternal-Fetal Medicine2021，3，2： | 1 |
| 3 | EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway显示文摘 | M.Alicia Cortés Ariel E. Cariaga-Martinez María V.T. Lobo Rosa M. Martín Orozco Omar Moti?o F.Javier Rodríguez-Ubreva Javier Angulo Pilar López-Ruiz Bego?a Colás | 2012 | Carcinogenesis2012，，6： | 1 |
| 4 | Postoperative radiotherapy in resected non-small cell lung cancer:The never-ending story显示文摘This manuscript collects in a joint and orderly manner the existing evidence at the present time about postoperative treatment with radiotherapy in non-small cell lung cancer.It also systematically reviews the current evidence,the international recommendations in the most relevant guidelines,the most controversial aspects in clinical and pathological staging,the specific technical aspects of radiotherapy treatment,and also collects all the potential risk factors that have been postulated as significant in the prognosis of these patients,evaluating the possibility of segmenting a particularly sensitive subpopulation with a high risk of relapse on which an adjuvant treatment with radiotherapy could have an impact on their clinical evolution.Finally,currently active trials that aspire to provide more evidence on this topic are reviewed. | Javier Serrano Patricia Calvo Crespo Begoña Taboada Ana Alvarez Gonzalez Rafael Garcia García Antonio Gomez Caamaño Juan Carlos Trujillo Reyes Xabier Mielgo-Rubio Felipe Couñago | 2021 | World Journal of Clinical Oncology2021，12，10： | 1 |
| 5 | GOECP/SEOR radiotherapy guidelines for small-cell lung cancer显示文摘Small cell lung cancer(SCLC)accounts for approximately 20%of all lung cancers.The main treatment is chemotherapy(Ch).However,the addition of radiotherapy significantly improves overall survival(OS)in patients with non-metastatic SCLC and in those with metastatic SCLC who respond to Ch.Prophylactic cranial irradiation reduces the risk of brain metastases and improves OS in both metastatic and non-metastatic patients.The 5-year OS rate in patients with limited-stage disease(non-metastatic)is slightly higher than 30%,but less than 5%in patients with extensive-stage disease(metastatic).The present clinical guidelines were developed by Spanish radiation oncologists on behalf of the Oncologic Group for the Study of Lung Cancer/Spanish Society of Radiation Oncology to provide a current review of the diagnosis,planning,and treatment of SCLC.These guidelines emphasise treatment fields,radiation techniques,fractionation,concomitant treatment,and the optimal timing of Ch and radiotherapy.Finally,we discuss the main indications for reirradiation in local recurrence. | Felipe Couñago Carolina de la Pinta Susana Gonzalo Castalia Fernández Piedad Almendros Patricia Calvo Begoña Taboada Antonio Gómez-Caamaño JoséLuis López Guerra Marisa Chust JoséAntonio GonzálezFerreira AnaÁlvarez González Francesc Casas | 2021 | World Journal of Clinical Oncology2021，12，3： | 1 |
| 6 | Bilateral gluteoplasty for fecal incontinence显示文摘 | Dr. Jose M. Devesa M.D. Jose M. Fernandez Madrid M.D. Bego?a Rodríguez Gallego M.D. Emilio Vicente M.D. Javier Nu?o M.D. Jose M. Enríquez M.D | 1997 | Diseases of the Colon & Rectum1997，，8： | 1 |
| 7 | Comparison of central corneal thickness using optical low-coherence reflectometry and spectral-domain optical coherence tomography显示文摘 | Alberto López-Miguel María Encarnación Correa-Pérez Silvia Miranda-Anta Darío Iglesias-Corti?as María Bego?a Coco-Martín Miguel J. Maldonado | 2012 | Journal of Cataract & Refractive Surgery2012，，5： | 1 |
| 8 | Bispecific sigma-1 receptor antagonism and mu-opioid receptor partial agonism:WLB-73502,an analgesic with improved efficacy and safety profile compared to strong opioids显示文摘Opioids are the most effective painkillers,but their benefit-risk balance often hinder their therapeutic use.WLB-73502 is a dual,bispecific compound that binds sigma-1(S1R)and mu-opioid(MOR)receptors.WLB-73502 is an antagonist at the S1R.It behaved as a partial MOR agonist at the G-protein pathway and produced no/unsignificantβ-arrestin-2 recruitment,thus demonstrating low intrinsic efficacy on MOR at both signalling pathways.Despite its partial MOR agonism,WLB-73502exerted full antinociceptive efficacy,with potency superior to morphine and similar to oxycodone against nociceptive,inflammatory and osteoarthritis pain,and superior to both morphine and oxycodone against neuropathic pain.WLB-73502 crosses the blood-brain barrier and binds brain S1R and MOR to an extent consistent with its antinociceptive effect.Contrary to morphine and oxycodone,tolerance to its antinociceptive effect did not develop after repeated 4-week administration.Also,contrary to opioid comparators,WLB-73502 did not inhibit gastrointestinal transit or respiratory function in rats at doses inducing full efficacy,and it was devoid of proemetic effect(retching and vomiting)in ferrets at potentially effective doses.WLB-73502 benefits from its bivalent S1R antagonist and partial MOR agonist nature to provide an improved antinociceptive and safety profile respect to strong opioid therapy. | Alba Vidal-Torres Begoña Fernández-Pastor Mónica García Eva Ayet Anna Cabot Javier Burgueño Xavier Monroy Bertrand Aubel Xavier Codony Luz Romero Rosalía Pascual Maria Teresa Serafini Gregorio Encina Carmen Almansa Daniel Zamanillo Manuel Merlos JoséMiguel Vela | 2023 | Acta Pharmaceutica Sinica B2023，13，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员